Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said
Follow-up monitoring In this phase, safety and effectiveness are judged over time, not assumed
Incorrect injection placement may lead to pain, poor drug absorption, or even nerve injury
Glutathione's Thiol Group and Chelation Potential The cysteine residue in glutathione carries a free thiol (-SH) group
US$ 26.67
US$ 21.34
US$ 20.75
US$ 20.18
US$ 22.50
US$ 22.33
US$ 25.26
